Ibio Inc Down 33.51% To $0.21 After Earnings

Ibio Inc (IBIO) said after close Tuesday that it broke even in quarter four 2022.

In the same quarter a year ago, the company lost $0.05 per share on revenue of $491 thousand.

The stock is down 33.51% to $0.21 after the report.

Ibio Inc's profit margins maintained as both earnings and revenue declined at the same pace.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

InvestorsObserver gives the stock a Bearish Sentiment score at the moment based on recent trading.

Ibio Inc has been a strong performer over the past few months, garnering a high Long-Term Technical Rank by InvestorsObserver of 81, putting Ibio Inc in the top 25% of stocks. The firm set a 52-week low on May 17, 2022 at $0.22 and set a 52-week high on September 28, 2021 at $1.13.

iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: biologics development and licensing activities, conducted within iBio, Inc.